Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TGM1 | P22735 | 1/20 | 0.37 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553620 | 0.71 | TGM2 (0.50) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL20379487 | 0.67 | TGM2 (0.50) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL4732340 | 0.65 | ALDH1A1 (0.62) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL31043510 | 0.65 | TGM2 (0.42) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL26026744 | 0.65 | TGM2 (0.48) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL25294152 | 0.63 | TGM2 (0.46) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL11331053 | 0.62 | TGM2 (0.53) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL22287107 | 0.62 | TGM2 (0.39) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL31043511 | 0.61 | TGM2 (0.42) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL14203835 | 0.61 | TGM2 (0.52) | TGM2F13A1LMNATGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682931-B2 | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof | UBE INDUSTRIES, LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| EP-3064489-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | Ube Industries, Ltd. (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | UBE INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | SLCO1B1, SLCO2B1, SLCO1B3 | TGM2 3268/4885F13A1 2290/4885LMNA 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.